EMA — authorised 26 May 2016
- Marketing authorisation holder: Amicus Therapeutics UK Ltd
- Status: approved
EMA authorised Galafold on 26 May 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 26 May 2016.
Amicus Therapeutics UK Ltd holds the EU marketing authorisation.